Metabolic & Weight

Best Peptides for Obesity: Evidence-Based Guide

Guide to peptides for obesity — semaglutide, tirzepatide, and GH secretagogues with evidence, dosing, and weight management protocols.

Affects 650 million adults worldwide; 42% of US adults

This page is for educational purposes only and does not constitute medical advice. Peptides discussed are research compounds. Always consult a qualified healthcare provider for diagnosis and treatment.

Understanding Obesity

Obesity is a chronic metabolic disease characterized by excess adipose tissue accumulation that impairs health. It involves complex interactions between genetic predisposition, hormonal dysregulation (leptin resistance, insulin resistance), gut microbiome, and environmental factors. It significantly increases risk of type 2 diabetes, cardiovascular disease, and certain cancers.

Common Symptoms

BMI ≥30 kg/m²

Excess body fat, especially visceral fat

Metabolic complications (insulin resistance, dyslipidemia)

Physical limitations and joint pain

Sleep apnea

Reduced quality of life

Conventional Treatments

Caloric restriction and dietary modificationPhysical activityGLP-1 receptor agonists (semaglutide, tirzepatide)OrlistatBariatric surgery (severe obesity)Behavioral therapy

How Peptides May Help

Semaglutide and tirzepatide are the most evidence-backed peptides for obesity, with clinical trials showing 15-22% body weight loss. They reduce appetite, slow gastric emptying, and improve metabolic parameters. GH secretagogues (ipamorelin, CJC-1295) support body recomposition through lipolysis and lean mass preservation.

Top Peptides for Obesity

1Tirzepatide

Very strong — FDA-approved, multiple Phase 3 RCTs

Mechanism: Dual GIP/GLP-1 receptor agonist; reduces appetite, slows gastric emptying, improves insulin sensitivity

Typical dose: 2.5mg/week titrating to 5-15mg/week

2Semaglutide

Very strong — FDA-approved, multiple Phase 3 RCTs

Mechanism: GLP-1 receptor agonist; reduces appetite and food intake, improves metabolic parameters

Typical dose: 0.25mg/week titrating to 1-2.4mg/week

3Ipamorelin

Moderate preclinical; limited human data for obesity

Mechanism: GH secretagogue; promotes lipolysis and lean mass preservation

Typical dose: 200-300mcg SubQ 2-3x daily

Suggested Starting Protocol

For significant weight loss: semaglutide or tirzepatide (FDA-approved, strongest evidence). For body recomposition without GLP-1 agonists: ipamorelin + CJC-1295 stack with caloric deficit and resistance training. Combine any peptide protocol with dietary modification and physical activity.

Important: Semaglutide and tirzepatide are FDA-approved for obesity and have the strongest evidence. Weight regain occurs after stopping GLP-1 agonists — they are chronic medications. GH secretagogues for obesity are experimental. Always combine with lifestyle modifications.

Frequently Asked Questions

Is tirzepatide better than semaglutide for obesity?

Head-to-head trials show tirzepatide produces greater weight loss (20-22% vs. 15-17% of body weight). Both are highly effective. Tirzepatide's dual GIP/GLP-1 mechanism appears to provide additive benefits.

Will I regain weight after stopping GLP-1 agonists?

Yes — most patients regain significant weight after stopping semaglutide or tirzepatide. These are chronic medications for weight management, not short-term treatments.

Can GH secretagogues help with obesity?

GH secretagogues (ipamorelin, CJC-1295) promote lipolysis and lean mass preservation, supporting body recomposition. However, they produce much less weight loss than GLP-1 agonists and are more appropriate for body recomposition than significant weight loss.

Related Conditions

Type 2 Diabetes metabolic syndrome sleep apnea cardiovascular

Find the right peptide for your biology

Take our 5-minute quiz to get a personalized peptide recommendation based on your specific goals and health profile.